- Reports: ESI may start 'price war' over new hepatitis C drugs
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- Senate passes Drug Quality and Security Act
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
- 21 health industry groups address FDA on proposed changes to generic drug label rules
DUBLIN — The Food and Drug Administration has approved a generic drug for high blood pressure made by Actavis, the company said Friday.
Actavis announced the approval of telmisartan immediate-release tablets in the 20-mg, 40-mg and 80-mg strengths, which it intends to release immediately.
The drug is a generic version of Boehringer Ingelheim's Micardis, which had sales of about $274 million during the 12-month period that ended in September, according to IMS Health. As the first company to successfully apply for approval of a generic version, Actavis has 180 days in which to compete exclusively against Boehringer Ingelheim's product, according to FDA regulations.